Our innovative OFM (open flow microperfusion) sampling technology is a valuable tool for PK-PD studies in neuroscience, dermatology, oncology, and biomarker research. Minimally invasive, membrane-free OFM probes enable access to the entire biochemical information of the interstitial fluid from brain and peripheral tissues, and thus opens up new horizons in pre-clinical and clinical drug testing.
Dr Thomas Birngruber and Dr Frank Sinner will present valuable insights on improved formulation screening and local dermal PK and PD using dOFM sampling.
This webinar will give you a concise overview of dOFM capabilities and introduce possible setups for preclinical and clinical studies. We will present several case studies for drug development, biomarker discovery and bioequivalence assessment. More information
Our experts will answer all your questions personally, such as:
Date: November 10, 2020
Time: 3:00 pm London / 10:00 am New York
Duration: 60 Minutes
FDA Video: The U.S. Food and Drug Administration recently published a video showing the potential of dermal open flow microperfusion (dOFM) for generic drug development.